LG AI Research and D&D Pharmatech sign agreement for oral peptide drugs

LG AI Research and D&D Pharmatech just teamed up to tackle one of peptide science’s biggest challenges: making oral peptide drugs a reality. The deal’s all about combining LG’s AI muscle with D&D’s biotech know-how to design peptides you don’t have to inject. Anyone following peptide research knows how stubborn peptides can be—fragile in the gut, tricky to absorb, a headache to deliver. The promise of an oral format opens the door for more practical, accessible research compounds.

Why does this matter? Oral peptides have been the holy grail for a while. Most peptides break down before they can get anywhere useful when taken by mouth. If this collaboration cracks the code, expect a surge in new research compounds and test protocols. It would mean less reliance on injections, easier studies, and way more flexibility for labs and researchers.

Here’s what stands out:

For researchers, this is a heads-up: oral peptide formats could be on the horizon. That means new opportunities for experiment design and easier workflows. It also raises the bar for vendors—new formats, better delivery, more options for your next project. If you want to stay on top of what’s coming, keep an eye on the peptide research index and check the vendor directory for sourcing updates.

Key takeaway: The race for oral peptide research compounds is heating up, and this partnership could move the finish line a lot closer.